Alvotech Enterprise Value History

Key Indicators . Enterprise Value . Stocks . USA . 
Stock . Alvotech
ALVO Stock  USD 3.26  0.06  1.87%   
Enterprise Value stood at 4.2 B as of December 31, 2025. This metric is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents. Over the last 16 observed reporting periods, this metric has remained relatively stable, showing minimal deviation from its historical mean (CV 7.7%). Complete Financial Overview
 
Enterprise Value  
 First Reported
2010-12-31
 Previous Quarter
4.22 billion
 Current Value
4.22 billion
 Quarterly Volatility
288.93 million
Macro event markers
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes

Latest Alvotech Enterprise Value Growth Pattern

ViewLast Reported 2.29 B10 Years Trend
Stable
   Enterprise Value   
       Timeline  

Enterprise Value Trend Statistics

A CV of 7.7% for Alvotech's Enterprise Value indicates low dispersion relative to the mean over 3 periods. The R-squared value of 0.10 is consistent with no statistically meaningful linear trend.
Arithmetic Mean 3,745,077,726
Geometric Mean 3,735,600,320
Coefficient Of Variation 7.71
Mean Deviation 165,694,078
Median 3,673,221,264
Standard Deviation 288,929,966
Sample Variance83480.5T
Range1.3B
R-Value 0.31
Mean Square Error80551.4T
R-Squared 0.1
Significance 0.23
Slope 17,671,906
Total Sum of Squares1335688.4T

Alvotech Enterprise Value History

Alvotech's Enterprise Value is tracked from 2024 through 2026, spanning 3 reported values, moving from 4.68 billion to 3.34 billion.
20263.34 billion
20254.22 billion
20244.68 billion

Correlation of Enterprise Value With Other Accounts

The matrix below shows pairwise correlations between Alvotech's Enterprise Value and related financial accounts. These coefficients measure linear association and do not imply causation.
Click cells to compare fundamentals

Related Fundamentals

Last ReportedEnd Of Year Estimate
Enterprise Value Multiple8.38x8.8x
Price To Sales Ratio2.44x2.32x
PTB Ratio-5.03-5.29
Days Sales Outstanding43.4141.24
Book Value Per Share-1.02-1.07

Methodology, Assumptions & Data Sources

The data below presents Alvotech's Enterprise Value through recent fiscal years. The regression slope and R-squared together indicate whether the directional trend is persistent or episodic. Alvotech's Enterprise Value is best evaluated in the context of Biotechnology sector operating characteristics.

Reported values for Alvotech are derived from periodic company reporting and market reference feeds and standardized for analysis. Sell-side coverage, where present, supplements the data shown. Reference data and historical patterns are presented and do not constitute an investment recommendation or advice.

Editorial review and methodology oversight provided by: Ellen Johnson, Member of Macroaxis Editorial Board
Tools
Analysis
Directory
Company
2026 Macroaxis LLC Made with in San Francisco
Privacy Terms Widgets Feedback
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and conditions page.